Home › Funds › BlackBarn Capital Partners LP › ABUS
BlackBarn Capital Partners LP position in ABUS
ARBUTUS BIOPHARMA CORP · Health Care
BlackBarn Capital Partners LP reported holding 2,500,000 shares of ABUS (ARBUTUS BIOPHARMA CORP) in its Q2 2026 13F filing — a position valued at US$12.0M, representing 1.10% of its reported portfolio and ranking #17 among its reported holdings. BlackBarn Capital Partners LP has disclosed ABUS holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BlackBarn Capital Partners LP's ABUS position evolved
BlackBarn Capital Partners LP first disclosed a stake in ABUS in Q1 2024 at 2,070,900 shares (US$5.3M). The position peaked in Q2 2026 at 2,500,000 shares, worth US$12.0M. Across 10 filings, BlackBarn Capital Partners LP increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 2,500,000 shares valued at US$12.0M. Notable position changes include a 35% increase in Q1 2026 (shares rose 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 2.07M | $5.34M | New |
| Q2 2024 | 2.07M | $6.40M | Hold |
| Q3 2024 | 2.07M | $7.97M | Hold |
| Q4 2024 | 2.34M | $7.66M | Add |
| Q1 2025 | 2.34M | $8.17M | Hold |
| Q2 2025 | 2.60M | $8.04M | Add |
| Q3 2025 | 2.00M | $9.08M | Reduce |
| Q4 2025 | 1.85M | $8.90M | Reduce |
| Q1 2026 | 2.50M | $11.25M | Add |
| Q2 2026 | 2.50M | $12.00M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABUS and 13F data
ABUS (ARBUTUS BIOPHARMA CORP) is a Health Care company. 43 other funds we track also report a position in ABUS — the largest reported positions include Whitefort Capital Management, LP (US$75.8M), Two Seas Capital LP (US$38.9M), Deltroit Asset Management (UK) LLP (US$5.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABUS
- Whitefort Capital Management, LP 15.79M sh · $75.81M · Q2 2026
- Two Seas Capital LP 8.14M sh · $38.93M · Q3 2026
- Deltroit Asset Management (UK) LLP 1.20M sh · $5.76M · Q2 2026
- Western Standard LLC 542.79K sh · $2.61M · Q2 2026
- Rangeley Capital, LLC 500.00K sh · $2.40M · Q2 2026
More on BlackBarn Capital Partners LP
FAQ
How long has BlackBarn Capital Partners LP held ABUS?
BlackBarn Capital Partners LP has disclosed ABUS holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is BlackBarn Capital Partners LP's current position in ABUS?
As of Q2 2026, BlackBarn Capital Partners LP holds 2.50M shares of ABUS (ARBUTUS BIOPHARMA CORP), valued at $12.00M, representing 1.10% of its reported portfolio and ranking #17.
Has BlackBarn Capital Partners LP been buying or selling ABUS?
In the latest 13F filing (Q2 2026), BlackBarn Capital Partners LP held unchanged its position in ABUS. The position peaked in Q2 2026 at 2.50M shares.
Which other funds hold ABUS?
Other major institutional holders of ABUS include Whitefort Capital Management, LP, Two Seas Capital LP, Deltroit Asset Management (UK) LLP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.